Venlafaxine updated on 07-01-2025

Neonatal medical care

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13135
R50103		 Marks (Controls exposed to Bupropion), 2021 Neonatal intensive care unit admission during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.17 [0.70;1.94] 33/132   91/406 124 132
ref
S13353
R51476		 Calderon-Margalit, 2009 Neonatal Intensiv Care Unit (NICU) during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 3.68 [0.76;17.80] -/9   -/2,493 - 9
ref
Total 2 studies 1.61 [0.59;4.41] 124 141
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Marks (Controls exposed to Bupropion), 2021Marks, 2021 1 1.17[0.70; 1.94]12413272%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Calderon-Margalit, 2009Calderon-Margalit, 2009 3.68[0.76; 17.80]-928%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 46% 1.61[0.59; 4.41]1241410.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls exposed to Bupropion;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.61[0.59; 4.41]12414146%NAMarks (Controls exposed to Bupropion), 2021 Calderon-Margalit, 2009 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 3.68[0.76; 17.81]-9 -NACalderon-Margalit, 2009 1 exposed to other treatment, sickexposed to other treatment, sick 1.17[0.70; 1.95]124132 -NAMarks (Controls exposed to Bupropion), 2021 1 Tags Adjustment   - Yes  - Yes 1.61[0.59; 4.41]12414146%NAMarks (Controls exposed to Bupropion), 2021 Calderon-Margalit, 2009 2 Monotherapy   - no or not specified  - no or not specified 3.68[0.76; 17.81]-9 -NACalderon-Margalit, 2009 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.17[0.70; 1.95]124132 -NAMarks (Controls exposed to Bupropion), 2021 1 All studiesAll studies 1.61[0.59; 4.41]12414146%NAMarks (Controls exposed to Bupropion), 2021 Calderon-Margalit, 2009 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.68[0.76; 17.81]-9 -NACalderon-Margalit, 2009 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.17[0.70; 1.95]124132 -NAMarks (Controls exposed to Bupropion), 2021 10.510.01.0